First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

ST. GALLEN, Switzerland–(BUSINESS WIRE)–Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, eff…